Search
Fremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018.
Nedaplatin
go.drugbank.com/drugs/DB13145ApprovedInvestigationalIt is less nephrotoxic than [DB00515] but has proven equally effective. It was approved for use in Japan in 1995.
Pyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigational[A231004] Acetylcholinesterase inhibitors have been the symptomatic treatment of choice in myasthenia gravis since the 1930s with the early use of [physostigmine] and [neostigmine]. … By inhibiting the breakdown of acetylcholine in the neuromuscular junction, they increase signalling and relieve symptoms.
Teicoplanin
go.drugbank.com/drugs/DB06149ApprovedInvestigationalWithdrawnAll teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseNirsevimab
go.drugbank.com/drugs/DB16258ApprovedInvestigational[L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.
Categories: Antiinfectives for Systemic UseValaciclovir
go.drugbank.com/drugs/DB00577ApprovedInvestigationalOne major use of valacyclovir is the treatment of genital herpes episodes or outbreaks. … It was initially approved by the FDA in 1995 [FDA label] and marketed by GlaxoSmithKline [L5671]. Valacyclovir is the L-valine ester of aciclovir.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseVaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. … In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI).
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseCyclandelate
go.drugbank.com/drugs/DB04838ApprovedWithdrawnCyclandelate is not approved for use in the U.S. or Canada, but is approved in various European countries.
Griseofulvin
go.drugbank.com/drugs/DB00400ApprovedVet approvedGriseofulvin may be given by mouth in the treatment of tinea infections.
Categories: Antifungals for Topical Use, Antifungals for Systemic UseCefdinir
go.drugbank.com/drugs/DB00535ApprovedInvestigationalCefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use